| Literature DB >> 26321681 |
Ping-Chih Ho1, Jessica Dauz Bihuniak2, Andrew N Macintyre3, Matthew Staron4, Xiaojing Liu5, Robert Amezquita6, Yao-Chen Tsui7, Guoliang Cui4, Goran Micevic8, Jose C Perales9, Steven H Kleinstein10, E Dale Abel11, Karl L Insogna2, Stefan Feske12, Jason W Locasale5, Marcus W Bosenberg13, Jeffrey C Rathmell3, Susan M Kaech14.
Abstract
Activated T cells engage aerobic glycolysis and anabolic metabolism for growth, proliferation, and effector functions. We propose that a glucose-poor tumor microenvironment limits aerobic glycolysis in tumor-infiltrating T cells, which suppresses tumoricidal effector functions. We discovered a new role for the glycolytic metabolite phosphoenolpyruvate (PEP) in sustaining T cell receptor-mediated Ca(2+)-NFAT signaling and effector functions by repressing sarco/ER Ca(2+)-ATPase (SERCA) activity. Tumor-specific CD4 and CD8 T cells could be metabolically reprogrammed by increasing PEP production through overexpression of phosphoenolpyruvate carboxykinase 1 (PCK1), which bolstered effector functions. Moreover, PCK1-overexpressing T cells restricted tumor growth and prolonged the survival of melanoma-bearing mice. This study uncovers new metabolic checkpoints for T cell activity and demonstrates that metabolic reprogramming of tumor-reactive T cells can enhance anti-tumor T cell responses, illuminating new forms of immunotherapy.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26321681 PMCID: PMC4567953 DOI: 10.1016/j.cell.2015.08.012
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582